Bloodstream Infections Caused by Multidrug Resistant Bacteria: Clinical and Microbiological Features and Mortality

Objectives: Bloodstream infections (BSI) are associated with high morbidity and mortality. The aim of our study is to determine whether there is a relationship between certain risk factors such as the underlying disease, patient’s medical history, or interventional procedures and multidrug resistant (MDR) bacterial infection and to determine the risk factors for mortality. Methods: Two hundred and twenty-two outpatients and inpatients who were diagnosed with bacteremia over a 6-month period were included in the study. 232 agents from 222 patients were isolated and tested for antimicrobial susceptibility. The relationship between patients demographic and clinical data and MDR was analyzed. Results: The most common microorganisms were Gram-negative bacteria (59.4%), Gram-positive bacteria (36.9%), Candida species (2.2%), and anaerobic bacteria (1.35%). The most common isolates were Escherichia coli 53 (22.8%), Staphylococcus aureus 35 (%15.1), Klebsiella pneumoniae 26 (11.2%), Pseudomonas spp. (n=17, 7.3%), Acinetobacter spp 17 (7.3%), and Enterococcus spp 14 (6%). Mi-croorganisms with the highest antimicrobial resistance observed were 82.3% in Acinetobacter baumannii , 64.5% in coagulase-negative staphylococci, 60.3% in E. coli , 50% in K. pneumoniae, and 27.2% in Enterobacterales spp. Most patients with BSI caused by MDR bacteria were in the intensive care unit (64%). Sepsis diagnosis, urinary catheter use, history of surgery, and use of broad-spectrum antibiotics as well as risk factors for antibiotic-resistant bacteremia, coronary artery disease, inappropriate empirical therapy, health-care-associated infections, urinary catheterization, and stay in the ICU were determined as risk factors for mortality. Conclusion: Our study identified the risk factors of BSI caused by MDR bacteria and helped to reveal the relationship between these factors and mortality.

[1]  J. Rodríguez-Baño,et al.  Treatments and Predictors of Mortality for Carbapenem-Resistant Gram-Negative Bacilli Infections in Malaysia: A Retrospective Cohort Study , 2022, Tropical medicine and infectious disease.

[2]  F. D. De Rosa,et al.  Ten Years of KPC-Kp Bloodstream Infections Experience: Impact of Early Appropriate Empirical Therapy on Mortality , 2022, Biomedicines.

[3]  Y. Hassan,et al.  Association of Multidrug Resistance Bacteria and Clinical Outcomes of Adult Patients with Sepsis in the Intensive Care Unit , 2022, Tropical medicine and infectious disease.

[4]  G. d’Ettorre,et al.  Time to Effective Therapy Is an Important Determinant of Survival in Bloodstream Infections Caused by Vancomycin-Resistant Enterococcus spp , 2022, International journal of molecular sciences.

[5]  Yongqiang Yang,et al.  Outcomes and Risk Factors of Bloodstream Infections Caused by Carbapenem-Resistant and Non-Carbapenem-Resistant Klebsiella pneumoniae in China , 2022, Infection and drug resistance.

[6]  E. Petinaki,et al.  Molecular characteristics and predictors of mortality among Gram-positive bacteria isolated from bloodstream infections in critically ill patients during a 5-year period (2012–2016) , 2020, European Journal of Clinical Microbiology & Infectious Diseases.

[7]  K. Laupland,et al.  Population-based risk factors for community-onset bloodstream infections , 2019, European Journal of Clinical Microbiology & Infectious Diseases.

[8]  C. Vandenbroucke-Grauls,et al.  Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review , 2019, Antimicrobial Resistance & Infection Control.

[9]  M. Reis,et al.  Bloodstream infections caused by multidrug-resistant gram-negative bacteria: epidemiological, clinical and microbiological features , 2019, BMC Infectious Diseases.

[10]  K. Laupland,et al.  Risk factors associated with bloodstream infections in end-stage renal disease patients: a population-based study , 2018, Infectious diseases.

[11]  E. Giné,et al.  Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance , 2018, PloS one.

[12]  K. Garey,et al.  Bacteremia in Patients With Liver Cirrhosis: Prevalence and Predictors of Multidrug Resistant Organisms , 2017, Journal of clinical gastroenterology.

[13]  Wen-Hung Wang,et al.  The epidemiology, antibiograms and predictors of mortality among critically-ill patients with central line-associated bloodstream infections. , 2017, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[14]  J. Thaden,et al.  Results from a 13-Year Prospective Cohort Study Show Increased Mortality Associated with Bloodstream Infections Caused by Pseudomonas aeruginosa Compared to Other Bacteria , 2017, Antimicrobial Agents and Chemotherapy.

[15]  S. Harthug,et al.  Burden of bloodstream infection in an area of Mid-Norway 2002-2013: a prospective population-based observational study , 2017, BMC Infectious Diseases.

[16]  R. Kullar,et al.  A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail. , 2017, The Lancet. Infectious diseases.

[17]  S. Yavuz,et al.  Healthcare-associated Gram-negative bloodstream infections: antibiotic resistance and predictors of mortality. , 2016, The Journal of hospital infection.

[18]  D. Szabo,et al.  Factors influencing antimicrobial resistance and outcome of Gram-negative bloodstream infections in children , 2016, Infection.

[19]  K. Peck,et al.  Risk factors and molecular epidemiology of community-onset, multidrug resistance extended-spectrum β-lactamase-producing Escherichia coli infections , 2016, The Korean journal of internal medicine.

[20]  P. Savelkoul,et al.  Prevalence and risk factors for carriage of ESBL-producing Enterobacteriaceae in Amsterdam , 2016, The Journal of antimicrobial chemotherapy.

[21]  N. Taneja,et al.  Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria , 2016, Microbiology insights.

[22]  Adil Rafiq Rather,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) , 2015 .

[23]  Alan P. Johnson,et al.  Antibiotic Stewardship Initiatives as Part of the UK 5-Year Antimicrobial Resistance Strategy , 2015, Antibiotics.

[24]  G. B. Orsi,et al.  Changed epidemiology of ICU acquired bloodstream infections over 12 years in an Italian teaching hospital. , 2015, Minerva anestesiologica.

[25]  N. Safdar,et al.  Attributable mortality of central line associated bloodstream infection: systematic review and meta-analysis , 2015, Infection.

[26]  G. Rossolini,et al.  Update on the antibiotic resistance crisis. , 2014, Current opinion in pharmacology.

[27]  D. Church,et al.  Population-Based Epidemiology and Microbiology of Community-Onset Bloodstream Infections , 2014, Clinical Microbiology Reviews.

[28]  C. Giaquinto,et al.  Current management of late onset neonatal bacterial sepsis in five European countries , 2014, European Journal of Pediatrics.

[29]  A. Marra,et al.  Nosocomial Bloodstream Infections in Brazilian Pediatric Patients: Microbiology, Epidemiology, and Clinical Features , 2013, PloS one.

[30]  M. Al-Hasan,et al.  Overall burden of bloodstream infection and nosocomial bloodstream infection in North America and Europe. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[31]  M. Antonelli,et al.  Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study , 2012, Intensive Care Medicine.

[32]  K. Kaye,et al.  Impact of Cefepime Therapy on Mortality among Patients with Bloodstream Infections Caused by Extended-Spectrum-β-Lactamase-Producing Klebsiella pneumoniae and Escherichia coli , 2012, Antimicrobial Agents and Chemotherapy.

[33]  A. Marra,et al.  Nosocomial Bloodstream Infections in Brazilian Hospitals: Analysis of 2,563 Cases from a Prospective Nationwide Surveillance Study , 2011, Journal of Clinical Microbiology.

[34]  Miguel Calvo Rebollar,et al.  Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. , 2011, The Journal of antimicrobial chemotherapy.

[35]  Vincent H Tam,et al.  Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. , 2010, The Journal of antimicrobial chemotherapy.

[36]  L. Dijkshoorn,et al.  An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii , 2007, Nature Reviews Microbiology.

[37]  Daniel J Sexton,et al.  Health CareAssociated Bloodstream Infections in Adults: A Reason To Change the Accepted Definition of Community-Acquired Infections , 2002, Annals of Internal Medicine.

[38]  H. Sørensen,et al.  Population-based study of the risk and short-term prognosis for bacteremia in patients with liver cirrhosis. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  S. Chevret,et al.  A one-year prospective study of nosocomial bacteraemia in ICU and non-ICU patients and its impact on patient outcome. , 2000, Journal of Hospital Infection.

[40]  D. Pittet,et al.  Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. , 1995, Archives of internal medicine.

[41]  Jay Steingrub,et al.  International study of the prevalence and outcomes of infection in intensive care units , 2009 .

[42]  R. Ramphal,et al.  Extended-spectrum beta-lactamases and clinical outcomes: current data. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.